on BIOSYNEX (EPA:ALBIO)
Biosynex sells its molecular biology business
Biosynex, a company listed on Euronext Growth, has completed the sale of its molecular biology business. This transaction follows the fulfillment of conditions precedent and approval by the bankruptcy judge. The sale agreement was signed on June 10, 2026, following the agreement of the relevant creditors.
This operation is part of Biosynex's strategy to refocus on Rapid Diagnostic Tests (RDTs) and Therapeutic Drug Monitoring (TDM). Concurrently, the liquidation of its subsidiary Avalun led to the acceptance of an offer for its financial assets.
In addition, Jérôme Silvestre resigned from his position as a censor on the Board of Directors for personal reasons effective May 30, 2026. Biosynex is thus continuing its growth strategy.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOSYNEX news